(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 December 2014 (24.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/205229 A8

(51) International Patent Classification:
A61K 31/445 (2006.01)

(21) International Application Number:
PCT/US2014/043204

(22) International Filing Date:
19 June 2014 (19.06.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/837,928 21 June 2013 (21.06.2013) US
61/877,832 13 September 2013 (13.09.2013) US

(71) Applicant *(for all designated States except BB, US)*: **IVAX INTERNATIONAL Gmbh** [CH/CH]; Alpenstrasse 2, CH-8640 Rapperswil (CH).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **BASSAN, Merav** [IL/IL]; 15a Ziporen St., 42206 Netanya (IL). **EYAL, Eli** [IL/IL]; Hahadas 12, Petah-tikva (IL). **HAGAI, Esther, Lukasiewicz** [IL/IL]; Aharon David Gordon 15, Tel Aviv (IL). **SVEINSDOTTER TEIGE WICKENBERG, Anna, Kristina** [SE/SE]; Klangvagen 29, S-22472 Lund (SE).


(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: USE OF HIGH DOSE PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE



Rand = randomisation; V = Visit, TC = telephone call; W = Week; D = Day; FU = Follow-up

Fig. 1

(57) Abstract: This invention provides a method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 135 mg of pridopidine is administered to the patient per day. This invention further provides a method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine hydrochloride such that greater than 90 mg of pridopidine is administered to the patient per day.

WO 2014/205229 A8

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
9 April 2015

(15) Information about Correction:
see Notice of 9 April 2015